Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Investor Presentation (2001)
24 slides from Getinge Ab Class B's investor presentation, 2001
Slide 1: GETINGE
GETINGE An expanding Medical-Technology group with focus on comprehensive solutions for infection control, surgical systems and care of elderly and disabled people Customers Acute Care Long term care Industry/Laboratories Net Sales appr. 7.5 billion SEK Associates 5 500 Manufacturing 20 production u
Slide 2: Business Scope 2000
Business Scope 2000 Business Areas Infection Control Extended Care Surgical Systems Sterilisation Hygiene Systems Surgical tables Disinfection Patient Handling Surgical lamps Wound Care Customer segments Industry Acute care Long term care
Slide 3: Market Development 2000
Market Development 2000 Total Long term care Acute care Industry Western Europe 50 % 63 % 36 % 44 % North America 39 % 33 % 45 % 43 % Asia, Australia 7% 3% 12 % 9% ROW 4% 1% 7% 4%
Slide 4: Extended Care
Extended Care Hygiene Systems Wound Care Patient Handling Complete solutions for institutional extended care: Nursing Homes, Hospitals, Assisted Living
Slide 5: Extended Care
Extended Care Hygiene Systems Patient Handling Wound Care Market 1 400 MSEK 1 700 MSEK 8 000 MSEK Growth 5-7% 8 - 10 % 8 - 10 % Getinge 55% Getinge 39% Hillrom US 25% Sakai JP 8% Sunrise US 12% KNCI US 20% Chiltern UK 4% Liko SE 7% Huntleigh UK 7% Guldman DK 5% Getinge 6%
Slide 6: Extended Care Strategic Corner-Stones
Extended Care Strategic Corner-Stones Product leadership Complete Solutions Positive outcomes
Slide 7: Extended Care Orders received (MSEK)
Extended Care Orders received (MSEK) extended care orders rcd 2000 1999 Change 2000 1999 Change per market Q4 Q4 FY FY USA and Canada 214 168 28% 771 744 4% Great Britain 171 124 38% 569 503 13% Germany 60 65 -7% 237 242 -2% Other W. Europe 159 115 38% 478 414 15% Rest of the world 23 21 10% 84 78 8
Slide 8: Extended Care Results (MSEK)
Extended Care Results (MSEK) 2000 1999 2000 1999 EC w Wc Q4 Q4 FY FY Net sales 634 515 2 111 2 008 Gross profit % 49,5% 52,6% 49,4% 52,4% Operating cost -199 -182 -719 -731 Operating profit 115 89 323 320 Operating margin% 18,1% 17,2% 15,3% 16,0%
Slide 9: Infection Control - Health Care
Infection Control - Health Care Disinfection Sterilization IT-solutions Load handling Complete Systems for: Central Processing Departments, Outpatient Surgery, Wards, Infectious Waste, Microbiology, Pharmacies
Slide 10: Infection Control - Industry
Infection Control - Industry Sterilization Washin Water Load Handling g Treatment Complete Systems for: Production, Research / Laboratories, Animal Care Facilities, Food Industry
Slide 11: Infection Control
Infection Control Sterilization Disinfection Market 6 200 MSEK 2 500 MSEK Growth 4% 5% Getinge 24% Getinge 27% Steris US 21% Miele DE 15% Sakura JP 8% Steris US 9% J & J US 7% Meiko DE 8% MMM DE 6% Bellimed CH 5% Fedegari IT 5%
Slide 12: Infection Control Health Care: From Product to Solution
Infection Control Health Care From Product to Solution Sterilizer Disinfector Load handling Complete Logistics Infection Information management Control Consumables After Sales service Solutions Education From Cost to Revenue
Slide 13: Infection Control Strategic Corner-Stones
Infection Control Strategic Corner-Stones Cost leadership Complete Solutions Service Infrastructure
Slide 14: Infection Control Orders received MSEK
Infection Control Orders received MSEK IC orders rcd 2000 1999 Change 2000 1999 Change per market Q4 Q4 FY FY Western Europe 353 334 6% 1 273 1 314 -3% USA and Canada 354 332 7% 1 299 1 146 13% Asia/Australia 60 56 8% 265 298 -11% Rest of the world 50 34 45% 208 126 65% Business area total 817 755 8
Slide 15: Infection Control Results (MSEK)
Infection Control Results (MSEK) 2000 1999 2000 1999 IC w US Q4 Q4 FY FY Net sales 984 895 3 081 2 811 Gross profit % 38,6% 39,4% 36,8% 38,6% Operating cost -219 -202 -768 -719 Operating profit 161 150 368 365 Operating margin% 16,4% 16,8% 11,9% 13,0%
Slide 16: Reasons for Expansion into the Surgical Systems Market
Business Area Surgical Systems Reasons for Expansion into the Surgical Systems Market The infection control market and the market for surgical systems is converging Getinge will become a more attractive and competent supplier to the healthcare industry The market for surgical systems is to a larg
Slide 17: Surgical Systems market shares MSEK
Surgical Systems market shares MSEK Surgical tables Surgical lights Ceiling Service Units Market: 4 000 M 2 000 M 1 000 M Growth: 5% 5% 10 - 15% Getinge 40% Getinge 20% Draeger DE 25% Miizuho JPN 18% Berchtold DE 20% Kreuzer DE 15% Steris US 15% Steris US 15% Getinge 6% Echman UK 7% Heraeus DE 15% J
Slide 18: Business Area Surgical Systems: A First Step
Business Area Surgical Systems A First Step To create o strong global player in the surgical field with world leadership position in: - Surgical tables - Surgical lights - Ceiling service units Distributed through own sales organisation in all major developed markets
Slide 19: Integration & Restructuring of Maquet and ALM
Integration & Restructuring of Maquet and ALM Synergies Production Closure of Charleston plant (USA) - transfer to Orléans(FR) and Rastatt(DE) Integration of Maquet infection control production with Business Area Infection Control Co-ordination of table production between Orléans(FR) and Rastatt
Slide 20: Integration & Restructuring of Maquet & ALM Synergies
Integration & Restructuring of Maquet & ALM Synergies Cost synergies are estimated to generate savings of 140 - 150 MSEK per annum within 2 years Cross-selling will enable Business Area Surgical Systems to grow faster than the industry during year 2 to 5 The divestiture of Ortho-Maquet will impro
Slide 21: Surgical Systems Growth Opportunities
Business Area Surgical Systems Growth Opportunities Continuous growth through acquisition principally lights and ceiling service units Evaluate new areas of interest in the surgical systems environment Develop strong cross selling capabilities Product innovation - IGS - Endoscopy - Integrated su
Slide 22: Getinge Group Objectives
Getinge Group Objectives To retain and develop world leadership position in prioritized business areas / business niches Growth in profit before tax of 15% over a business cycle Organic growth 5 % Internally generated cash flow to sustain an external growth rate of I0 %
Slide 23: Getinge Industrier Results (MSEK)
Getinge Industrier Results (MSEK) Gind res 2000 1999 Change 2000 1999 Change Q4 Q4 FY FY Orders received 1 461 1 268 15% 5 243 4 932 6% Net sales 1 633 1 429 14% 5 254 4 885 8% * EBITDA 329 288 15% 892 880 1% * Operating profit 278 241 15% 697 692 1% Operating margin 17,0% 16,8% 0,2% 13,3% 14,2% -0,
Slide 24: Balance Sheets (MSEK)
Balance Sheets (MSEK) Gind balance Assets 2000-12-31 1999-12-31 Goodwill 2 451 1 013 Fixed assets 1 620 816 Stock-in-trade 1 269 765 Receivables 2 457 1 625 Liquid assets 235 159 Total Assets 8 031 4 378 Shareholders' equity & Liabilities Shareholders' equity 1 931 1 561 Minority interest 9 – Intere